TY - JOUR
T1 - Gender affirming treatment and employment rate in 3,812 Danish transgender persons and 38,120 controls
AU - Glintborg, Dorte
AU - Møller, Jens-Jakob Kjer
AU - Rubin, Katrine Hass
AU - Lidegaard, Øjvind
AU - T'Sjoen, Guy
AU - Larsen, Mie-Louise Julie Ørsted
AU - Hilden, Malene
AU - Andersen, Marianne Skovsager
PY - 2024/11/18
Y1 - 2024/11/18
N2 - Objective: Gender-affirming care could be associated with higher employment rate. We assessed employment rates in transgender persons compared to controls and demographic, health, and treatment-related factors associated with employment in transgender persons. Methods: National register-based cohort study in Danish persons with diagnosis code of gender dysphoria during year 2000-2021. Five age-matched controls of the same sex at birth and 5 age-matched controls of the other sex at birth were included. The date of study inclusion was the first date of transgender diagnosis. Employment was the primary study outcome. Results: The cohort included 3812 transgender persons and 38 120 cisgender controls. The median age (interquartile range) was 19 (15; 24) years for transgender men, n = 1993 and 23 (19; 33) years for transgender women, n = 1819. In transgender men compared to control cisgender women, the odds ratio (OR) (95% CI) for employment was 0.33 (0.29; 0.38) before study inclusion and 0.24 (0.20; 0.29) in the fifth calendar year after index; in transgender women compared to control cisgender men, corresponding ORs were 0.30 (0.70; 0.34) and 0.21 (0.18; 0.25). Similar findings were observed between transgender persons and cisgender controls of other sex. Use of gender-affirming hormone in transgender men increased probability of employment at all time points after 5 years (OR 1.61 [95% CI: 1.08; 2.42], P = .02). In transgender women, use of hormone treatment was not associated with changed employment rates at 5 years (OR 1.31 [0.94; 1.82], P = .11). Conclusion: Masculinizing hormone treatment was associated with higher probability of employment.
AB - Objective: Gender-affirming care could be associated with higher employment rate. We assessed employment rates in transgender persons compared to controls and demographic, health, and treatment-related factors associated with employment in transgender persons. Methods: National register-based cohort study in Danish persons with diagnosis code of gender dysphoria during year 2000-2021. Five age-matched controls of the same sex at birth and 5 age-matched controls of the other sex at birth were included. The date of study inclusion was the first date of transgender diagnosis. Employment was the primary study outcome. Results: The cohort included 3812 transgender persons and 38 120 cisgender controls. The median age (interquartile range) was 19 (15; 24) years for transgender men, n = 1993 and 23 (19; 33) years for transgender women, n = 1819. In transgender men compared to control cisgender women, the odds ratio (OR) (95% CI) for employment was 0.33 (0.29; 0.38) before study inclusion and 0.24 (0.20; 0.29) in the fifth calendar year after index; in transgender women compared to control cisgender men, corresponding ORs were 0.30 (0.70; 0.34) and 0.21 (0.18; 0.25). Similar findings were observed between transgender persons and cisgender controls of other sex. Use of gender-affirming hormone in transgender men increased probability of employment at all time points after 5 years (OR 1.61 [95% CI: 1.08; 2.42], P = .02). In transgender women, use of hormone treatment was not associated with changed employment rates at 5 years (OR 1.31 [0.94; 1.82], P = .11). Conclusion: Masculinizing hormone treatment was associated with higher probability of employment.
KW - Adolescent
KW - Adult
KW - Case-Control Studies
KW - Cohort Studies
KW - Denmark/epidemiology
KW - Employment/statistics & numerical data
KW - Female
KW - Gender Dysphoria/epidemiology
KW - Humans
KW - Male
KW - Registries/statistics & numerical data
KW - Sex Reassignment Procedures/statistics & numerical data
KW - Transgender Persons/statistics & numerical data
KW - Young Adult
KW - gender-affirming hormone
KW - mental health
KW - medicine prescription
KW - socioeconomic status
KW - transgender
KW - register-based
U2 - 10.1210/clinem/dgae351
DO - 10.1210/clinem/dgae351
M3 - Journal article
C2 - 38771642
SN - 0021-972X
VL - 109
SP - 3076
EP - 3086
JO - The Journal of Clinical Endocrinology & Metabolism
JF - The Journal of Clinical Endocrinology & Metabolism
IS - 12
ER -